Acorda Therapeutics Inc Enterprise value
What is the Enterprise value of Acorda Therapeutics Inc?
The Enterprise value of Acorda Therapeutics Inc is $569.58M
What is the definition of Enterprise value?
Enterprise value is a measure of a company’s total market value. It is calculated as market capitalization with debt, minority interest, and preferred shares minus total cash and cash equivalents.
ttm (trailing twelve months)
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Enterprise value of companies in the Health Care sector on NASDAQ compared to Acorda Therapeutics Inc
What does Acorda Therapeutics Inc do?
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Companies with enterprise value similar to Acorda Therapeutics Inc
- Heidelberger Druckmaschinen AG has Enterprise value of $567.55M
- IQE Plc has Enterprise value of $568.18M
- Artemis Gold has Enterprise value of $568.28M
- Royal Nickel has Enterprise value of $568.77M
- DCB Bank has Enterprise value of $568.97M
- Social Capital Hedosophia IV has Enterprise value of $569.42M
- Acorda Therapeutics Inc has Enterprise value of $569.58M
- DCB Bank has Enterprise value of $569.78M
- HeidelbergCement India has Enterprise value of $569.90M
- Wajax has Enterprise value of $570.24M
- Hollywood Bowl Plc has Enterprise value of $571.02M
- Digital Media Solutions has Enterprise value of $571.18M
- Jamna Auto Industries has Enterprise value of $571.40M